JPMorgan analyst Lisa Gill lowered the firm’s price target on CVS Health to $86 from $101 and keeps an Overweight rating on the shares. The firm believes diversified managed care organizations and hospitals remain best positioned within its large cap coverage universe. Within managed care, a more defensive approach is still the best way to play the group over the near-term, the analyst tells investors in a research note. JPMorgan remains more cautious on Medicare Advantage given lack of visibility on 2024 cost trends and uncertainty around 2025 bids.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS seeks partner for new Oak Street primary care sites, Bloomberg reports
- CVS Health seeking PE partner to fund Oak Street growth, Bloomberg says
- CVS Health: Core trends ‘very consistent’ with 2023
- CVS Health call volume above normal and directionally bullish
- CVS Health price target lowered to $80 from $100 at Argus